ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1

Abstract

Epithelial to mesenchymal transition (EMT), and the reverse mesenchymal to epithelial transition (MET), are known examples of epithelial plasticity that are important in kidney development and cancer metastasis. Here we identify ASPP2, a haploinsufficient tumour suppressor, p53 activator and PAR3 binding partner, as a molecular switch of MET and EMT. ASPP2 contributes to MET in mouse kidney in vivo. Mechanistically, ASPP2 induces MET through its PAR3-binding amino-terminus, independently of p53 binding. ASPP2 prevents β-catenin from transactivating ZEB1, directly by forming an ASPP2-β-catenin-E-cadherin ternary complex and indirectly by inhibiting β-catenin's N-terminal phosphorylation to stabilize the β-catenin-E-cadherin complex. ASPP2 limits the pro-invasive property of oncogenic RAS and inhibits tumour metastasis in vivo. Reduced ASPP2 expression results in EMT, and is associated with poor survival in hepatocellular carcinoma and breast cancer patients. Hence, ASPP2 is a key regulator of epithelial plasticity that connects cell polarity to the suppression of WNT signalling, EMT and tumour metastasis.

The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties

“…In the canonical Wnt pathway, Wnt signaling inhibits β-catenin degradation, which can result in changes in various genes at the transcription level, such as the transcription factors HOXA5 (Ordonez-Moran et al, 2015) and ZEB1 (Wang et al, 2014). Several studies have revealed that activation of the Wnt signaling pathway is a hallmark of many human cancers (Clevers, 2006).…”

The crosstalk between lncRNA and microRNA in cancer metastasis: orchestrating the epithelial-mesenchymal plasticity

“…Many experimental and clinical studies have been tried to underlie the biology of this metastatic cascade. And there comes epithelial-mesenchymal plasticity, involving “changing faces” between epithelial cells and mesenchymal cells [4, 5]. Epithelial cells can undergo multiple biochemical changes to get a mesenchymal cell phenotype (EMT), and its reversible process, mesenchymal-epithelial transition (MET), can revert the mesenchymal cells back to epithelial cells [6, 7].…”

Epac1 links prostaglandin E2 to β-catenin-dependent transcription during epithelial-to-mesenchymal transition

“…In an in vivo model of colorectal carcinoma, it has been demonstrated that nuclear β-catenin and subsequent activation of TCF, a transcription factor commonly associated with nuclear β-catenin, increases the expression of the important EMT transcription factor zinc finger E-box binding homeobox 1 protein (ZEB1) [17], of which the expression has the most consistent inverse correlation with E-cadherin expression across different types of carcinomas [18]. This mechanism was recently confirmed in a pancreatic cancer model [19] and in an in vivo kidney model for EMT [20]. Thus, activation of β-catenin/TCF-dependent transcription (referred to as β-catenin-dependent transcription) can induce EMT, thereby down-regulating E-cadherin expression, further releasing β-catenin form the adherens junction, creating a positive feedback loop that attenuates cell-cell adhesion and reinforces EMT in transformed cells.…”